-
Mashup Score: 1Home - ClinicalTrials.gov - 2 year(s) ago
Explore 415,175 research studies in all 50 states and in 220 countries. See listed clinical studies related to the coronavirus disease (COVID-19) ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine. IMPORTANT: Listing a study does not mean it has been evaluated by the U.S….
Source: www.clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@BijoyTelivala @thomaseliotlew Enrollment started in 2018, well after Ibr approval. However, looks like only 3/87 centers are in the US. I dont know enough about standard of care in the other countries. https://t.co/Z5tBsGHljQ
-
-
Mashup Score: 0Changing causes of death in persons with haematological cancers 1975–2016 - Leukemia - 2 year(s) ago
Causes of death in persons with haematological cancers include the index cancer, a new cancer or a seemingly unrelated cause such as cardio-vascular disease. These causes are complex and sometimes confounded. We analyzed trends in cause of death in 683,333 persons with an index haematological cancer diagnosed in 1975–2016 reported in the Surveillance, Epidemiology and End Results dataset….
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Limiting toxicities should be a trial and treatment priority in CLL. A new SEER analysis shows that patients will CLL are more likely to die from second cancers or cardiac disease then CLL. https://t.co/VMkyBfKoBG https://t.co/z92JApuSVq
-
-
Mashup Score: 0Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial - 2 year(s) ago
PURPOSE Among Bruton’s tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL). METHODS Patients with previously treated CLL with centrally…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
So although acalabrutinib may have same efficacy as ibrutinib, the 6.6% decrease in arrhythmias and 5% increase in grade 3 HTN is very important. https://t.co/smZT4BzzGl
-
-
Mashup Score: 0
Blood Cancer Journal – Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
A study of 1.2k CLL patients patients treated at Mayo Clinic had very similar causes of death; 35% progressive CLL, 6% infection, 16% second cancers. CLL related deaths increase with increasing IPI. https://t.co/ped1mA4ly5
-
-
Mashup Score: 0
17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (i) a 1-hour intravenous infusion of 1.5 MU of streptokinase; (ii) one month of 160 mg/day enteric-coated aspirin; (iii) bot …
Source: PubMedCategories: Expert Picks, Latest HeadlinesTweet-
This subgroup analysis was actually included in the paper(!!), not the supplement, to make a point - subgroups can often be produced by the play of chance. Trial: https://t.co/rDt1F0V4lh commentary: https://t.co/vpHQHdu1RU
-
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Source: New England Journal of MedicineCategories: Expert Picks, Latest HeadlinesTweet-
To be fair, in the POLARIX paper, they initially described this subgroup analysis as exploratory and focused more in the results on the subgroups w/o a clear benefit. They conclude the heterogeneity needs to be assessed in further trials. Sounds fair. https://t.co/nufKWpklz7
-
-
Mashup Score: 0Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study - 2 year(s) ago
Venetoclax with dose-adjusted EPOCH-R showed an acceptable safety profile at the recommended phase 2 dose and had encouraging preliminary activity in this population at high risk of adverse outcomes, and is worthy of further study. The combination is being investigated in Alliance 051701 (NCT03984448).
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@timfenske 100% Agree an additional lesson is to be cautious interpreting safety signals from phase 1 trials. "Venetoclax with dose-adjusted EPOCH-R showed an acceptable safety profile at the recommended phase 2 dose " https://t.co/mNAdnfSIs0
-
-
Mashup Score: 7
General Sessions Late-Breaking Abstracts Session Clinical Trials, Biological, Lymphomas, Clinical Research, Diseases, Aggressive Lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies Hervé Tilly, MD1, Franck Morschhauser, MD, PhD2*, Laurie H. Sehn, MD3, Jonathan W. Friedberg, MD 4, Marek Trněný, MD5, Jeff P. Sharman, MD6, Charles Herbaux, MD7, John…
Source: ash.confex.comCategories: Expert Picks, Latest HeadlinesTweet-
🚨Out now POLARIX🚨 PFS was superior with pola-R-CHP vs R CHOP (HR 0.73; 95% CI: 0.57–0.95; P<0.02). 2-year PFS rate was 76.7% with pola-R-CHP vs 70.2% with R-CHOP. No difference in EOT CR by PET No difference in OS Safety similar - including PN https://t.co/KrMwTKQON2
-
-
Mashup Score: 1
General Sessions Late-Breaking Abstracts Session Clinical Trials, Biological, Lymphomas, Non-Hodgkin Lymphoma, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Aggressive Lymphoma, Therapies, Lymphoid Malignancies Michael R. Bishop, MD1, Michael Dickinson, MBBS2, Duncan Purtill3*, Pere Barba, MD, PhD4*, Armando Santoro5*,…
Source: ash.confex.comCategories: Expert Picks, Latest HeadlinesTweet-
Tisa-cel no better then SOC HDCT->Auto for early relapse aggressive LBCL is a ASH LBA - will need to figure out how to make sense of the negative trial in might of the two positive trials. All targeted similar population. https://t.co/k6GYBBIALe
-
@Eddie_Cliff Looks like we are nearing the end... only 2 trials listed in https://t.co/wxyYzqkS4i with chlorambucil (both in China), a few with FCR , but still a handful with BR (which to be fair is fine if they are for IgVH mutated)